Research shows that fat cells in obese people release harmful packages containing a protein called ANGPTL2 that damages insulin-producing cells in the pancreas. According to Gram Research analysis of this 2026 study, removing ANGPTL2 from fat cells improved blood sugar control by 31 percent in mice and increased insulin secretion by 82 percent. The protein damages pancreatic cells by triggering a stress response pathway, and blocking this pathway restored cell function. These findings identify a new target for treating type 2 diabetes, though human studies are still needed.
Scientists discovered how obesity damages the insulin-producing cells in your pancreas. According to Gram Research analysis, fat cells release tiny packages called exosomes containing a protein called ANGPTL2 that travels to pancreatic cells and damages them. When researchers removed this protein from fat cells in obese mice, the pancreatic cells worked better and the mice had improved blood sugar control. This finding could lead to new treatments for type 2 diabetes by targeting this harmful communication between fat tissue and the pancreas.
Key Statistics
A 2026 research study in Diabetologia found that removing ANGPTL2 from fat cells in obese mice improved glucose tolerance by 31 percent, with the glucose area under the curve decreasing from 2300 to 1584 mmol/l times minutes.
Research shows that pancreatic cells exposed to exosomes lacking ANGPTL2 increased insulin secretion by 82 percent, from 6.0 percent to 10.9 percent of total insulin content when stimulated with glucose.
A 2026 study demonstrated that ANGPTL2 increases stress signaling in pancreatic cells by approximately 2.8-fold, and blocking this stress pathway with experimental drugs reversed the harmful effects on insulin production.
Research found that blocking the stress response pathway with multiple different drugs all protected pancreatic cell function, confirming that this pathway is the critical mechanism through which ANGPTL2 causes diabetes-related damage.
The Quick Take
- What they studied: How fat cells send harmful signals to insulin-producing cells in the pancreas, and whether blocking one specific protein could prevent this damage
- Who participated: Laboratory studies using mouse fat cells, mouse pancreatic cells, and living mice fed a high-fat diet to mimic obesity
- Key finding: Removing a protein called ANGPTL2 from fat cells improved pancreatic cell function and blood sugar control in obese mice. Mice with this protein removed showed a 31 percent improvement in glucose tolerance compared to control mice
- What it means for you: This research identifies a new target for treating type 2 diabetes by blocking harmful signals from fat tissue. However, these are early findings in mice, and human studies are needed before any new treatments become available
The Research Details
Researchers used multiple approaches to understand how obesity damages pancreatic cells. First, they grew fat cells in the lab and exposed pancreatic cells to substances released by these fat cells. They then studied living mice that were fed a high-fat diet to become obese. Some of these mice had a specific gene removed from their fat cells to prevent them from making the harmful protein ANGPTL2. The researchers measured how well the pancreatic cells worked and how well the mice controlled their blood sugar.
The team also performed detailed molecular studies to understand exactly how the harmful protein damages pancreatic cells. They looked at which proteins interact with each other and tested whether blocking specific steps in this damage pathway could restore pancreatic cell function. This combination of lab studies, animal studies, and molecular investigations provides strong evidence for how the process works.
The research design is particularly thorough because it shows the problem exists, demonstrates that removing the harmful protein fixes it, and explains the exact mechanism of how the damage occurs. This three-part approach makes the findings more convincing than any single type of experiment alone.
Understanding how obesity damages insulin-producing cells is crucial because type 2 diabetes affects hundreds of millions of people worldwide. Previous research showed that obesity causes problems, but scientists didn’t fully understand the specific signals traveling between fat tissue and the pancreas. This study identifies a concrete target that could be blocked with future medications. By pinpointing ANGPTL2 as a key harmful messenger, researchers can now develop drugs to stop this specific signal without affecting other important body functions.
This research was published in Diabetologia, a highly respected journal focused on diabetes research. The study used multiple complementary approaches, which strengthens confidence in the findings. The researchers tested their ideas in living animals, not just in isolated cells, which is important because the whole body is more complex than a dish of cells. The findings were consistent across different experiments, suggesting the results are reliable. However, this is animal research in mice, so results may not directly translate to humans. The study did not specify the exact number of mice used in each experiment, which is a minor limitation.
What the Results Show
When researchers removed the ANGPTL2 protein from fat cells in obese mice, the mice showed dramatic improvements in blood sugar control. The glucose tolerance test, which measures how well the body handles sugar, improved by 31 percent. Specifically, the area under the glucose curve decreased from 2300 to 1584 mmol/l times minutes, indicating much better blood sugar regulation.
In detailed laboratory studies, pancreatic cells exposed to exosomes (tiny packages) from fat cells without ANGPTL2 showed significantly better insulin secretion. When pancreatic cells were stimulated with glucose, they released 1.8 times more insulin in the treated group compared to controls, increasing from 6.0 percent to 10.9 percent of total insulin content.
The researchers discovered that ANGPTL2 damages pancreatic cells by activating a stress response pathway. The protein increases activity of a stress signal called EIF2 alpha by approximately 2.8-fold, which then triggers a cascade of harmful signals that damage the insulin-producing cells and cause them to lose their specialized identity.
When researchers blocked this stress pathway using experimental drugs, they could prevent the damage caused by ANGPTL2. This demonstrates that the stress pathway is the key mechanism through which ANGPTL2 harms pancreatic cells, and blocking this pathway could potentially reverse the damage.
Beyond blood sugar control, the study found that pancreatic cells exposed to harmful exosomes lost their specialized characteristics. Cells that normally produce only insulin started producing other hormones and showed signs of becoming less specialized. When ANGPTL2 was removed, these cells maintained their proper identity and function. The research also showed that ANGPTL2 accumulates specifically inside pancreatic cells when delivered by exosomes, suggesting these tiny packages are an effective delivery system for the harmful protein. Additionally, blocking the stress response pathway with multiple different drugs all produced similar protective effects, confirming that this pathway is the critical target.
Previous research established that obesity causes pancreatic cell dysfunction, but the specific signals responsible were unclear. This study advances the field by identifying ANGPTL2 as a key harmful messenger and showing that exosomes are the delivery vehicles. Earlier work suggested that fat tissue communicates with other organs through exosomes, but this is among the first studies to demonstrate this mechanism specifically in type 2 diabetes. The finding that blocking the stress response pathway can reverse damage aligns with emerging research showing that cellular stress contributes to diabetes development. This work provides a more complete picture of how obesity causes diabetes than previously available.
This research was conducted entirely in mice, and results may not directly apply to humans. The study did not specify the exact number of animals used in each experiment, making it difficult to assess statistical power. The research focused on one specific protein and pathway, so other harmful signals from fat tissue may also contribute to pancreatic cell damage. The study used laboratory-grown fat cells and pancreatic cells in some experiments, which are simpler than cells in a living body. Long-term effects were not studied, so it’s unclear whether blocking ANGPTL2 would provide lasting benefits. Finally, the research did not examine whether this approach would work in humans or what side effects might occur with long-term treatment.
The Bottom Line
Based on this research, blocking ANGPTL2 or the stress pathway it activates represents a promising target for new type 2 diabetes treatments. The evidence is strong in mice but preliminary in humans. People with type 2 diabetes should continue following their doctor’s current treatment recommendations while researchers develop and test new drugs based on these findings. Weight loss through diet and exercise remains the most proven approach to improve pancreatic cell function. This research suggests that future medications targeting ANGPTL2 could complement existing treatments.
This research is most relevant to people with type 2 diabetes or those at high risk due to obesity. Healthcare providers treating diabetes should be aware of this new target for drug development. Researchers studying obesity and diabetes will find this work particularly valuable. People with prediabetes or metabolic syndrome may benefit from future treatments based on these findings. However, current treatments remain the standard of care until human studies confirm these results.
In mice, blocking ANGPTL2 improved blood sugar control relatively quickly, but the exact timeline is not specified. If pharmaceutical companies develop drugs targeting this pathway, human clinical trials would typically take 5 to 10 years before any new medication becomes available. Even after approval, it may take additional time to determine whether the drug works as well in humans as it did in mice. People should not expect new treatments based on this research to be available in the near term.
Frequently Asked Questions
What is ANGPTL2 and why does it harm pancreatic cells?
ANGPTL2 is a protein released by fat cells in obese people. It travels in tiny packages called exosomes to pancreatic cells and activates a stress response pathway that damages insulin-producing cells. Blocking this protein or the stress pathway it triggers restores pancreatic cell function.
Can blocking ANGPTL2 treat type 2 diabetes in humans?
This research in mice shows promising results, but human studies are needed. Researchers are now developing drugs to target ANGPTL2 or the stress pathway it activates. New treatments based on this research may become available in 5 to 10 years if clinical trials succeed.
How does obesity cause pancreatic cell damage according to this research?
Fat cells in obese people release exosomes containing ANGPTL2. These packages enter pancreatic cells and trigger a stress response that damages insulin production. Removing ANGPTL2 from fat cells prevents this damage and improves blood sugar control by 31 percent in mice.
What lifestyle changes might help reduce ANGPTL2 levels?
This study focused on the protein itself rather than lifestyle factors. However, weight loss through diet and exercise is known to reduce harmful signals from fat tissue. Reducing processed foods high in saturated fat may help, since these foods increase ANGPTL2 production in fat cells.
Is this research directly applicable to human type 2 diabetes treatment?
This is early-stage research conducted in mice. While the findings are promising and identify a specific target for drug development, human clinical trials are required before any new treatment becomes available. Current diabetes medications remain the standard of care.
Want to Apply This Research?
- Track fasting blood glucose levels weekly and record weight, diet quality, and exercise minutes daily. Monitor these metrics over 4-week periods to identify trends in blood sugar control and identify which lifestyle changes correlate with improvements
- Use the app to set a goal of reducing processed foods high in saturated fat by 50 percent, since these foods increase the harmful ANGPTL2 signals described in this research. Log meals and track which foods correlate with better blood sugar readings
- Create a monthly dashboard showing trends in fasting glucose, weight, and lifestyle factors. Compare these trends to identify which combination of diet and exercise changes produces the best blood sugar control for your individual body
This article summarizes research findings from animal studies and should not be interpreted as medical advice. The research was conducted in mice, and results may not directly apply to humans. People with type 2 diabetes should continue following their doctor’s treatment recommendations and not make changes based on this research alone. New treatments based on these findings are not yet available. Consult with a healthcare provider before making any changes to diabetes management or lifestyle. This research identifies a potential future treatment target but does not represent current clinical practice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.